title: Putting the cardiovascular safety of aromatase inhibitors in patients with early breast cancer into perspective: a systematic review of the literature.
abstract: In the adjuvant setting, the third-generation aromatase inhibitors (AIs) anastrozole, letrozole and exemestane are recommended at some point during treatment, either in the upfront, switch after tamoxifen or extended treatment setting after tamoxifen in postmenopausal patients with hormone receptor-positive early breast cancer. AIs have demonstrated superior disease-free survival and overall benefit-to-risk profiles compared with tamoxifen. Potential adverse events, including cardiovascular (CV) side effects, should be considered in the long-term management of patients undergoing treatment with AIs. AIs reduce estrogen levels by inhibiting the aromatase enzyme, thus reducing the levels of circulating estrogen. This further reduction in estrogen levels may potentially increase the risk of developing CV disease. This systematic review evaluated published clinical data for changes in plasma lipoproteins and ischaemic CV events during adjuvant therapy with AIs in patients with hormone receptor-positive early breast cancer. The electronic databases MEDLINE, EMBASE, Derwent Drug File and BIOSIS were searched to identify English-language articles published from January 1998 to 15 April 2011 that reported data on AIs and plasma lipoproteins and/or ischaemic CV events. Overall, available data did not show any definitive patterns or suggest an unfavourable effect of AIs on plasma lipoproteins from baseline to follow-up assessment in patients with hormone receptor-positive early breast cancer. Changes that occurred in plasma lipoproteins were observed soon after initiation of AI therapy and generally remained stable throughout the studies. Available data do not support a substantial risk of ischaemic CV events associated with adjuvant AI therapy; however, studies with longer follow-up are required to better characterize the CV profile of AIs.
authors.affiliation: Epidemiology, Worldwide Safety Strategy, Pfizer Inc., New York, NY, USA.
authors.forename: Muhammad
authors.initials: M
authors.lastname: Younus
authors.forename: Michelle
authors.initials: M
authors.lastname: Kissner
authors.forename: Lester
authors.initials: L
authors.lastname: Reich
authors.forename: Nicola
authors.initials: N
authors.lastname: Wallis
mesh_terms: D047072:Aromatase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced; D006801:Humans; D006937:Hypercholesterolemia / Q000139:chemically induced
chemical_list: D047072:Aromatase Inhibitors
references.citation: Eur Heart J. 1996 Aug;17 Suppl D:15-9
references.pmid: 8869877
references.citation: Eur J Intern Med. 2008 Dec;19(8):592-7
references.pmid: 19046724
references.citation: J Clin Oncol. 2008 Apr 20;26(12):1965-71
references.pmid: 18332472
references.citation: J Clin Oncol. 2005 Aug 1;23(22):5126-37
references.pmid: 15983390
references.citation: J Clin Oncol. 2005 Aug 1;23(22):5138-47
references.pmid: 16009955
references.citation: Br J Cancer. 2006 Jul 17;95(2):153-8
references.pmid: 16835585
references.citation: Curr Pharm Des. 2011;17(9):861-70
references.pmid: 21418031
references.citation: Acta Oncol. 2005;44(2):134-41
references.pmid: 15788292
references.citation: Ann Oncol. 2008 May;19(5):877-82
references.pmid: 18332043
references.citation: J Lipid Res. 2006 Oct;47(10):2223-32
references.pmid: 16864897
references.citation: J Clin Oncol. 2007 Jul 1;25(19):2664-70
references.pmid: 17563395
references.citation: Lancet. 2007 Feb 17;369(9561):559-70
references.pmid: 17307102
references.citation: Circulation. 2004 Jul 13;110(2):227-39
references.pmid: 15249516
references.citation: Lancet. 2005 Aug 6-12;366(9484):455-62
references.pmid: 16084253
references.citation: Lancet Oncol. 2006 Aug;7(8):633-43
references.pmid: 16887480
references.citation: Br J Cancer. 2005 Aug;93 Suppl 1:S23-7
references.pmid: 16100522
references.citation: Ann Oncol. 2005 May;16(5):707-15
references.pmid: 15817595
references.citation: Ann Oncol. 2007 Jul;18(7):1133-44
references.pmid: 17675394
references.citation: Eur J Cancer. 2006 Nov;42(17):2968-75
references.pmid: 16963261
references.citation: Lancet. 2005 Apr 2-8;365(9466):1225; author reply 1225-6
references.pmid: 15811447
references.citation: Breast Cancer Res. 2009;11(3):R35
references.pmid: 19531217
references.citation: Lancet. 2002 Jun 22;359(9324):2131-9
references.pmid: 12090977
references.citation: Breast Cancer Res Treat. 2007 Nov;106(1):1-9
references.pmid: 17211535
references.citation: Lancet. 2005 May 14-20;365(9472):1687-717
references.pmid: 15894097
references.citation: J Natl Cancer Inst. 1990 Aug 15;82(16):1327-32
references.pmid: 2199681
references.citation: Oncologist. 2007 Oct;12(10):1156-64
references.pmid: 17962609
references.citation: Circulation. 2010 Feb 23;121(7):e46-e215
references.pmid: 20019324
references.citation: Cancer. 2009 May 1;115(9):1813-26
references.pmid: 19235248
references.citation: N Engl J Med. 2003 Nov 6;349(19):1793-802
references.pmid: 14551341
references.citation: Ann Oncol. 2006 Jun;17 Suppl 7:vii10-4
references.pmid: 16760270
references.citation: Cancer. 2008 Jan 15;112(2):260-7
references.pmid: 18041059
references.citation: N Engl J Med. 2004 Mar 11;350(11):1081-92
references.pmid: 15014181
references.citation: Ann Oncol. 2009 Jan;20(1):49-55
references.pmid: 18678766
references.citation: N Engl J Med. 2009 Aug 20;361(8):766-76
references.pmid: 19692688
references.citation: Oncologist. 2008 Dec;13(12):1224-34
references.pmid: 19091778
references.citation: Lancet Oncol. 2008 Jan;9(1):45-53
references.pmid: 18083636
references.citation: Ann Oncol. 2007 Sep;18 Suppl 8:viii26-35
references.pmid: 17890211
references.citation: Breast Cancer. 2010 Jul;17(3):212-7
references.pmid: 19526308
references.citation: J Clin Oncol. 2008 Apr 20;26(12):1972-9
references.pmid: 18332471
references.citation: Anticancer Drugs. 2005 Sep;16(8):879-83
references.pmid: 16096437
references.citation: Clin Breast Cancer. 2006 Feb;6 Suppl 2:S58-64
references.pmid: 16595028
references.citation: J Clin Oncol. 2008 Apr 20;26(12):1948-55
references.pmid: 18332475
references.citation: Eur J Cancer. 2007 Nov;43(17):2523-31
references.pmid: 18029171
references.citation: J Intern Med. 1999 Dec;246(6):521-8
references.pmid: 10620095
references.citation: N Engl J Med. 2005 Dec 29;353(26):2747-57
references.pmid: 16382061
references.citation: J Natl Cancer Inst. 2005 Sep 7;97(17):1262-71
references.pmid: 16145047
references.citation: J Clin Oncol. 1986 Apr;4(4):459-71
references.pmid: 2856857
references.citation: Ann Oncol. 2011 Aug;22(8):1777-82
references.pmid: 21285133
references.citation: Lancet Oncol. 2006 Dec;7(12):991-6
references.pmid: 17138220
references.citation: Lancet. 2005 Jan 1-7;365(9453):60-2
references.pmid: 15639680
references.citation: Breast Cancer Res. 2007;9(3):R28
references.pmid: 17477859
references.citation: J Clin Oncol. 2010 Aug 10;28(23):3784-96
references.pmid: 20625130
references.citation: Lancet. 1998 May 16;351(9114):1451-67
references.pmid: 9605801
references.citation: Breast Cancer Res Treat. 2005 Sep;93(1):61-6
references.pmid: 16184460
references.citation: J Clin Oncol. 2007 Dec 20;25(36):5715-22
references.pmid: 17998546
references.citation: Expert Opin Pharmacother. 2009 Jun;10(9):1435-47
references.pmid: 19445563
references.citation: Breast Cancer Res Treat. 2010 Jun;121(2):379-87
references.pmid: 20390343
references.citation: Am Heart J. 2007 Feb;153(2):182-8
references.pmid: 17239675
references.citation: J Clin Oncol. 2007 Feb 10;25(5):486-92
references.pmid: 17200148
references.citation: Cancer. 2003 Nov 1;98(9):1802-10
references.pmid: 14584060
references.citation: J Clin Oncol. 2011 Mar 20;29(9):1117-24
references.pmid: 21321298
references.citation: Lancet. 2011 Jan 22;377(9762):321-31
references.pmid: 21247627
references.citation: Oncology. 2006;70(4):301-5
references.pmid: 17047401
references.citation: J Pharm Sci. 1997 Jul;86(7):876-9
references.pmid: 9232532
references.citation: Lancet Oncol. 2010 Dec;11(12):1135-41
references.pmid: 21087898
references.citation: Mutat Res. 2005 Dec 11;591(1-2):247-63
references.pmid: 16083919